Phaseline

Companies › Gain Therapeutics

Gain Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GT-02287–Phase 1Parkinson Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06732180GT-02287Phase 1Parkinson DiseaseNeurologyNov 2025

From the company's SEC filings

Cash of $13m on 2026-06-30; operating cash outflow about $19m a year; runway about 8 months at that burn, to Mar 2027

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.